Confirmation Of High Efficacy Of HPV Vaccine Against Precancerous Cervical Lesions And Protective Effect Of Vaccination Programs
The findings of the PATRICIA study are reported in an article Online First and in a future edition of The Lancet. It shows that the HPV-16/18 AS04-adjuvanted vaccine (GlaxoSmithKline) has high efficacy against the precancerous cervical lesions that can eventually lead to cervical cancer. There is confirmation that the vaccine also shows cross-protective efficacy against other oncogenic (that cause cancer) Human Papillomavirus (HPV) types closely related to HPV-16/18. In addition, it also shows efficacy in the cohorts relevant to universal mass vaccination and catch-up programs. The article is written by Dr Jorma Paavonen, of the University of Helsinki, Finland, and collaborators.
Mental Health